Mylan operates through three principal subsidiaries: Mylan Pharmaceuticals (generic pharmaceuticals); Mylan Technologies, (producer of generic and branded transdermal patches); and UDL Laboratories, (U.S.-supplier of unit dose pharmaceuticals). Mylan Laboratories, Inc., through its subsidiaries, engages in the development, manufacture, marketing, licensing, and distribution of generic, brand, and branded generic pharmaceutical products in the United States. Additionally, Mylan operates a fully integrated specialty pharmaceutical business, Dey Pharma, which produces innovative medicinal therapies, including EpiPen® Auto-Injector.

Acquired Companies: Mylan Bertek Pharmaceuticals, Somerset Pharmaceuticals, DEY L.P., Dow Hickam Pharmaceuticals, Matrix Laboratories Limited, Penederm, UDL Laboratories, Bioniche Pharma USA, LLC